Correction: Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome.
作者信息
Narvaez Javier, Canadillas Elena, Castellvi Ivan, Alegre Juan Jose, Vicens-Zygmunt Vanesa, Bermudo Guadalupe, Vidal-Montal Paola, Molina Molina Maria, Nolla Joan Miquel
机构信息
Department of Rheumatology, Hospital Universitario de Bellvitge. Bellvitge Biomedical Research Institute (IDIBELL), Feixa Llarga, s/n, Hospitalet de Llobregat, Barcelona, 08907, Spain.
Department of Rheumatology, Hospital Cl?nico, Universitario Lozano Blesa, Zaragoza, Spain.
出版信息
Arthritis Res Ther. 2024 Jul 9;26(1):128. doi: 10.1186/s13075-024-03357-y.
Abstract
摘要
相似文献
1
Correction: Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome.
Arthritis Res Ther. 2024 Jul 9;26(1):128. doi: 10.1186/s13075-024-03357-y.
2
Rituximab in the Treatment of Interstitial Lung Disease Associated with Antisynthetase Syndrome: A Multicenter Retrospective Case Review.
J Rheumatol. 2018 Jun;45(6):841-850. doi: 10.3899/jrheum.170541. Epub 2018 Apr 1.
3
Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response.
J Rheumatol. 2016 Aug;43(8):1566-74. doi: 10.3899/jrheum.150844. Epub 2016 Jun 1.
4
Jo1-antisynthetase syndrome and severe interstitial lung disease with organising pneumonia on histopathology with favourable outcome on early combined treatment with corticosteroids, mycophenolate mofetil and rituximab.
BMJ Case Rep. 2019 Sep 12;12(9):e231006. doi: 10.1136/bcr-2019-231006.
5
Rituximab effect in severe progressive connective tissue disease-related lung disease: preliminary data.
Rheumatol Int. 2020 May;40(5):719-726. doi: 10.1007/s00296-020-04545-0. Epub 2020 Mar 10.
6
Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome.
Respir Med. 2012 Apr;106(4):581-7. doi: 10.1016/j.rmed.2012.01.001. Epub 2012 Jan 24.
7
Interstitial lung disease associated with the idiopathic inflammatory myopathies and the antisynthetase syndrome: recent advances.
Curr Opin Rheumatol. 2014 Nov;26(6):684-9. doi: 10.1097/BOR.0000000000000104.
8
Successful treatment of antisynthetase syndrome presenting as rhabdomyolysis with rituximab.
Rheumatol Int. 2018 Jun;38(6):1125-1130. doi: 10.1007/s00296-018-4025-1. Epub 2018 Apr 11.
9
Oxygen-Dependent Patient with Antisynthetase Syndrome Associated Interstitial Lung Disease Responds Promptly to Rituximab with Rapid Pulmonary Function Improvement.
Mediterr J Rheumatol. 2017 Sep 29;28(3):153-156. doi: 10.31138/mjr.28.3.153. eCollection 2017 Sep.
10
Rituximab and Cyclophosphamide in Antisynthetase Syndrome-related Interstitial Lung Disease: An Observational Retrospective Study.
J Rheumatol. 2020 Nov 1;47(11):1678-1686. doi: 10.3899/jrheum.190505. Epub 2020 Mar 15.
本文引用的文献
1
Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome.
Arthritis Res Ther. 2024 Jun 18;26(1):122. doi: 10.1186/s13075-024-03353-2.
Zotero 插件